These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35479302)

  • 1. Targeting
    Granowicz EM; Jonas BA
    Onco Targets Ther; 2022; 15():423-436. PubMed ID: 35479302
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment.
    Chomczyk M; Gazzola L; Dash S; Firmanty P; George BS; Mohanty V; Abbas HA; Baran N
    Front Pharmacol; 2024; 15():1409210. PubMed ID: 39161899
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Shin DY
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
    Daver NG; Maiti A; Kadia TM; Vyas P; Majeti R; Wei AH; Garcia-Manero G; Craddock C; Sallman DA; Kantarjian HM
    Cancer Discov; 2022 Nov; 12(11):2516-2529. PubMed ID: 36218325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
    Pereira MP; Herrity E; Kim DDH
    Ann Hematol; 2024 Apr; 103(4):1049-1067. PubMed ID: 37770618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cluzeau T; Loschi M; Fenaux P; Komrokji R; Sallman DA
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and new treatment approaches in TP53 mutated AML.
    Hunter AM; Sallman DA
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I Treat
    Loschi M; Fenaux P; Cluzeau T
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139679
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation.
    Jang JE; Hwang DY; Eom JI; Cheong JW; Jeung HK; Cho H; Chung H; Kim JS; Min YH
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.
    Testa U; Castelli G; Pelosi E
    Mediterr J Hematol Infect Dis; 2023; 15(1):e2023038. PubMed ID: 37435040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of mutations in TP53 mutated AML.
    Welch JS
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?
    Wang C; Sallman DA
    Cancer J; 2022 Jan-Feb 01; 28(1):51-61. PubMed ID: 35072374
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Molica M; Mazzone C; Niscola P; de Fabritiis P
    Front Oncol; 2020; 10():610820. PubMed ID: 33628731
    [No Abstract]   [Full Text] [Related]  

  • 15. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.
    Yan B; Claxton D; Huang S; Qiu Y
    Exp Hematol; 2020 Jul; 87():13-19. PubMed ID: 32569759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.
    Asghari H; Talati C
    Curr Opin Hematol; 2020 Mar; 27(2):66-75. PubMed ID: 31922971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
    Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
    Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
    Barbosa K; Li S; Adams PD; Deshpande AJ
    Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    George B; Kantarjian H; Baran N; Krocker JD; Rios A
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are We Moving the Needle for Patients with
    Shallis RM; Bewersdorf JP; Stahl MF; Halene S; Zeidan AM
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.